Targeting Podoplanin for the Treatment of Osteosarcoma
Ai Takemoto(Japanese Foundation For Cancer Research), Naoya Fujita(Japanese Foundation For Cancer Research), Ryohei Katayama(Japanese Foundation For Cancer Research), Asami Kobayashi(Chemotherapy Foundation), Mamoru Kakino(Gifu Pharmaceutical University), Yuki Funauchi(Japan Association for Development of Community Medicine), Marie Lebel(Chemotherapy Foundation), Kengo Takeuchi(Japanese Foundation For Cancer Research), Kazue Tsuji‐Takayama(Statens Serum Institut), Seiichi Matsumoto(Fukuda Denshi (Japan)), Kenji Ichihara(API (Japan)), Satoshi Takagi(Japanese Foundation For Cancer Research), Takao Ukaji(Juntendo University), Miho Takami(Chemotherapy Foundation), Yoshiya Sugiura(Japanese Foundation For Cancer Research), Keisuke Ae(The Cancer Institute Hospital), Minoru Sugawara, Tetsuo Noda(Japanese Foundation For Cancer Research), Tokuichi Kawaguchi(The Cancer Institute Hospital), Nobuhiko Gyobu(API (Japan))
Cited by 29
Related Papers
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
|Nature Communications|2017|409
IP <sub>3</sub> Receptor Types 2 and 3 Mediate Exocrine Secretion Underlying Energy Metabolism
|Science|2005|317
Role of hepatic STAT3 in brain-insulin action on hepatic glucose production
|Cell Metabolism|2006|294
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283